Beta2 sympathomimetics

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 07.10.2021

Dieser Artikel auf Deutsch

Synonym(s)

beta2 agonist; beta2 agonists; beta2-receptor agonists; beta2-sympathomimetic; (e) Long acting beta2-agonist; ( e ) Short acting beta2-agonist; LABA; SABA; β2 receptor agonists; β2-Sympathomimetics

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Beta2 sympathomimetics or beta2 receptor agonists belong to the group of bronchodilators. Their name is derived from their ability to activate the beta2-receptors. These are involved in the transmission of stimuli in a part of the sympathetic nervous system.

ClassificationThis section has been translated automatically.

Examples of short-acting beta-2-symptathomimetic drugs (SABA):

Examples of long-acting beta2 sympathomimetics (LABA) for inhalation:

LABA for oral administration:

Numerous combination preparations of long-acting beta2 sympathomimetics and inhaled glucocorticoids are available.

Pharmacodynamics (Effect)This section has been translated automatically.

A basic distinction is made between the

  • long-acting beta2-sympathomimetics: long-acting beta-2-sympathomimetics = Long acting beta2-agonist- LABA, for long-term therapy or prevention of seizures. The effect lasts for about 12 to 24 hours. The substances are often used in combination with an inhaled glucocorticoid, since beta-2 sympathomimetics themselves have no anti-inflammatory activity.

and the

  • short-acting beta-2 sympathomimetics: = Short acting beta2-agonist -SABA /= rapid-acting beta-2 agonists-RABA (rapid-acting beta-2 sympathomimetics), with rapid onset of action for the treatment of acute symptoms. The effect sets in within a few minutes and lasts for about three to six hours.

This type of drug, known as uLABA (ultra Long Acting Beta 2 Agonists), is available with a further extended duration of action and only requires a single daily dose (e.g. indacaterol) (Beier J 2009).

The fast-acting substances (such as salbutamol, fenoterol and reproterol) are mainly used as so-called "relievers" in the acute therapy of obstructive respiratory diseases, whereas the long-acting substances (salmeterol and formoterol) are used as "controllers" in long-term therapy.

Spectrum of actionThis section has been translated automatically.

Beta-2 sympathomimetics are mainly used as topical agents (beta-2 sympathomimetics are mostly inhaled as a metered dose aerosol, spray or solution via inhalers) in bronchial asthma and obstructive pulmonary diseases (salbutamol, terbutaline, formoterol, salmeterol). They activate theβ2 receptors of the smooth bronchial muscles. Some substances are also used as oral forms of application (bambuterol, clenbuterol). They lead via bronchospasmolysis to a reduction in airway resistance. This effect is mainly due to the opening of the Ca++ -activated Kv-channels which are placed in the plasma membrane of the muscle cells. The opening of these channels leads to a hyperpolarization of the plasma membrane and thus to a reduced influx of Ca++ ions via voltage-dependent Ca++ channels. This leads to relaxation of the smooth muscle cell.

Apart from this effect on bronchial muscle tone, beta2 sympathomimetics activate the mucociliary clearing function. They also inhibit the release of inflammatory mediators from mast cells and other inflammatory cells.

IndicationThis section has been translated automatically.

Bronchial asthma, chronic bronchitis, emphysema.

Limited indicationThis section has been translated automatically.

Pregnancy, aortic stenosis, poorly controlled diabetes mellitus, limited glucose tolerance, severe CHD, fresh myocardial infarction.

Undesirable effectsThis section has been translated automatically.

Typical side effects occur mainly with systemic use. These include an increase in heart rate, palpitations, headaches, tremors, restlessness, nausea and muscle cramps (see also under the individual drugs).

The β2 receptor-induced activation of the Na+/K+-ATPase in muscle cells leads to the development of passagere hypokalemias.

The activation of β2 receptors on hepatocytes can lead to increased hepatic glucose production and to an increase in blood sugar.

The cause of the skeletal muscle hypertrophy observed mainly with systemic application is unclear (Cave: use of beta2 sympathomimetics as doping agent = clenbuterol doping, is also used in calf fattening!) Especially in endurance sports clenbuterol acts as a performance enhancing drug.

Allergic reactions, anaphylactic shock

InteractionsThis section has been translated automatically.

See Table 1.

ContraindicationThis section has been translated automatically.

Hypersensitivity to the active substance, severe hyperthyroidism, hypertrophic obstructive cardiomyopathy.

LiteratureThis section has been translated automatically.

  1. Beier J (2009) Bronchodilator effects of indacaterol and formoterol in patients with COPD, Pulm Pharmacol Ther 22:492-496.
  2. Buhl, R., et al.: S2k guideline for diagnosis and therapy of patients with asthma. In: Pneumology 2017; 71: 849-919
  3. Graefe KH et al. Obstructive respiratory diseases. In: Graefe KH et al (Eds) Pharmacology and Toxicology. Georg Thieme Publisher Stuttgart S.533
  4. Pfaar, O. et al.(2014) S2k guideline for (allergen-) specific immunotherapy for IgE-mediated allergic diseases. Allergo J Int 23: 282
  5. Ring, J. et al.(2014) S2k guideline on acute therapy and management of anaphylaxis. Allergo J Int 23: 96-112.

TablesThis section has been translated automatically.

Major drug interactions of β2-sympathomimetic drugs

Anticholinergics

Cardiac arrhythmias, tachycardia.

Antidepressants, tricyclic.

Cardiac NW of β2-sympathomimetics ↑

Cardiac glycosides

Cardiac arrhythmias, cardiac glycoside toxicity ↑

Insulin

Hyperglycemia

MAO inhibitors

RR decline, cardiac arrhythmias, avoid combination

Metformin

Hyperglycemia

β -receptor blockers

Bronchospasm, β-sympathomimetic effect ↓

Sulfonylureas

Hyperglycemia

Sympathomimetics

Reciprocal toxicity ↑

Theophylline

Cardiac arrhythmias, tachycardia

Authors

Last updated on: 07.10.2021